30 documents found, page 1 of 3
Transmural Remission Improves Clinical Outcomes Up to 5 years in Crohn's Disease
Raimundo Fernandes, S; Serrazina, J; Ayala Botto, I; Leal, T; Guimarães, A; Lemos Garcia, J; Rosa, I; Prata, R; Carvalho, D; Neves, J; Campelo, PIntroduction: Evidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavailable. Less stringent but more reachable targets such as isolated endoscopic (IER) or radiologic remission (IRR) may also be acceptable options in the long-term. Methods: Multicenter retrospective study including 404 CD patients evaluated by magnetic resonance enterography and colon...
Composite Outcomes in Observational Studies of Ulcerative Colitis: a Systematic...
Magro, F; Alves, C; Santiago, M; Ministro, P; Lago, P; Correia, L; Gonçalves, R; Carvalho, D; Portela, F; Dias, C; Dignass, A; Danese, SBackground: Ulcerative colitis (UC) has been the focus of numerous observational studies over the years and a common strategy employed in their design is the use of composite and aggregate outcomes. Objective: This systematic review and meta-analysis aims to identify composite and aggregate outcomes of observational studies in UC and to evaluate how the number and type of variables included and the length of fo...
Impact of montelukast as add on treatment to the novel coronavirus pneumonia (C...
Tavares, M; Farraia, M; Silva, S; Ribeiro, AM; Severo, M; Paciência, I; Ribeiro, R; Hespanhol, V; Guimarães, T; Almeida, J; Magro, F; Sarmento, ABackground: Montelukast, a safe drug widely use in asthmatic patients, may be an adjuvant in the treatment of Covid-19, either by improving lung injury and inflammation, or by acting as an anti-viral drug. We aim to assess the efficacy and safety of montelukast as add-on treatment in patients with Covid-19. Methods: We propose a randomized, controlled, parallel, open-label trial involving 160 hospitalized adult...
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Pinto-Lopes, P; Melo, F; Afonso, J; Pinto-Lopes, R; Rocha, C; Melo, D; Macedo, G; Dias, CC; Carneiro, F; Magro, FINTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD). METHODS: We evaluated a prospectively recruited cohort, consisting of 101 patients with IBD, using validated clinical indexes; 22 patients with ulcerative colit...
Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phen...
Sousa, HT; Gullo, I; Castelli, C; Dias, CC; Rieder, F; Carneiro, F; Magro, FINTRODUCTION:In Crohn's disease (CD), the assessment of transmural inflammation and fibrosis is of utmost importance. This study aimed to quantify these parameters in CD ileal specimens and correlate them with disease progression.METHODS:This is a retrospective unicentric study based on the analysis of archived specimens (n = 103) of primary ileal resection. Data were retrieved from a prospective national infla...
Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulatio...
Pereira, MS; Durães, C; Catarino, TA; Costa, JL; Cleynen, I; Novokmet, M; Krištic, J; Štambuk, J; Conceição-Neto, N; Machado, JC; Marcos-Pinto, ROBJECTIVES: The impact of genetic variants (single nucleotide polymorphisms [SNPs]) in the clinical heterogeneity of ulcerative colitis (UC) remains unclear. We showed that patients with UC exhibit a deficiency in MGAT5 glycogene transcription in intestinal T cells associated with a hyperimmune response. Herein, we evaluated whether MGAT5 SNPs might functionally impact on T cells glycosylation and plasma IgG gl...
Comparing the Continuous Geboes Score With the Robarts Histopathology Index: De...
Magro, F; Lopes, J; Borralho, P; Lopes, S; Coelho, R; Cotter, J; Oliveira, A, et al.Background and aims: The histological status of ulcerative colitis [UC] patients in clinical and endoscopic remission has gained space as an important prognostic marker and a key component of disease monitoring. Our main aims were to compare two histological indexes-the continuous Geboes score [GS] and the Robarts Histopathology index [RHI]-regarding their definitions of histological remission and response, and...
Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endosc...
Magro, F; Lopes, S; Silva, M; Coelho, R; Portela, F; Branquinho, D; Correia, L; Fernandes, S; Cravo, M; Caldeira, P; Sousa, H T; Patita, M; Lago, PBackground and aims: Golimumab has an established exposure-response relationship in patients with ulcerative colitis [UC]. However, the association of serum golimumab trough levels [TL] with objective markers of disease activity, such as endoscopic and histological activity scores and concentrations of biomarkers, remains less understood. This report describes the relationship of serum golimumab TL at the end o...
Accuracy of the new rapid test for monitoring adalimumab levels
Rocha, C; Afonso, J; Lago, P; Arroja, B; Vieira, AI; Dias, CC; Magro, FThe loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available r...
Soluble Human Suppression of Tumorigenicity 2 Is Associated with Endoscopic Act...
Magro, F; Lopes, S; Silva, M; Coelho, R; Portela, F; Branquinho, D; Correia, L; Fernandes, S; Cravo, M; Caldeira, P; Tavares de Sousa, H; Patita, MBackground: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab. Methods: We conducted an open-label single-arm multicentre prospective study. At screening/baseline, week 6 (W6) an...